Biotech’s biggest unicorn just took a billion-dollar haircut.
One of Moderna Therapeutics’ largest investors slashed its assessment of the company’s value by 34 percent, a painful write-down that comes as the ambitious young biotech struggles to retain talent and make good on its lofty promises to upend the drug industry.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.